Summary of Significant Accounting Policies - Research and development expenditure (Details) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
|
| Summary of Significant Accounting Policies | |||
| Acquired in-process R&D expensed | $ 52,000 | $ 2,316,000 | |
| Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration] | Research and Development Expense | Research and Development Expense | Research and Development Expense |
| Amount of in process R & D credit | $ 1,840,000 | ||
| Reimbursable R&D tax and expenditure credits | $ 11,467,000 | $ 15,542,000 | $ 30,226,000 |
| X | ||||||||||
- Definition Amount of in-process research and development expenditure credit. No definition available.
|
| X | ||||||||||
- Definition Reimbursement Of research and development tax and expenditure credit. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Indicates line item in statement of income or comprehensive income that includes writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|